Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Fentanyl in Angioplasty: What Is the Price of More Comfort During the Procedure?

Fentanyl is a potent opiate commonly administered in the cath lab. Recently, questions on its safety have been raised by research demonstrating that intravenous morphine significantly delays the absorption of oral P2Y12 platelet inhibitors. The mechanism might be slowed gastric emptying.

Fentanilo en la angioplatia: ¿Cuál es el precio de un mayor confort en el procedimiento?

The Platelet Aggregation with tiCagrelor Inhibition and FentanYl (PACIFY) trial enrolled 212 patients undergoing indicated angioplasty and randomized them to receive the procedure with or without fentanyl. Furthermore, all participants received subcutaneous lidocaine and intravenous midazolam besides 180 mg of ticagrelor as antiplatelet agent.


Read also: MitraClip Procedure Can Be Performed without General Anesthesia”.


Blood samples were taken in order to analyze the plasmatic concentration of ticagrelor 0.5, 1, 2, 4, and 24 hours after the load. Platelet function was also measured at 2 hours with the VerifyNow system.

 

The group receiving fentanyl presented significantly lower plasmatic concentrations of ticagrelor and higher platelet reactivity with the addition of ADP 2 hours after the load.

 

No differences in ticagrelor concentration were observed at 4 hours.


Read also: “The SOURCE 3 Confirms the Good Outcomes of the SAPIEN 3 at One Year Followup”.


In a pain survey with a 1-10 scale, patients who received fentanyl reported a 1.5 maximum pain vs. 2.3 reported by patients who did not receive the drug (p = 0.14).

 

One patient who received fentanyl experienced acute stent thrombosis and another presented catheter thrombosis. There were no thrombotic events in patients who did not receive fentanyl.

 

The post-procedural levels of ultra-sensitive troponin were significantly higher in the group receiving fentanyl, which raises questions on the clinical importance of the interaction between these drugs.

 

Conclusion

Routine use of fentanyl as part of sedation in coronary angioplasty reduces the absorption of ticagrelor and delays platelet inhibition, without comfort improvement as a counterpart.

 

Editorial

These results are added to the list of prior reports on how morphine delays the absorption of clopidogrel, prasugrel, and ticagrelor.

 

The prophylactic administration of fentanyl at the start of catheterization should be reconsidered.

 

Original title: Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial.

Reference: John W. McEvoy et al. Circulation. 2017 Oct 18. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...